Literature DB >> 22414859

Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders.

Vikas Kotagal1, Martijn L T M Müller, Daniel I Kaufer, Robert A Koeppe, Nicolaas I Bohnen.   

Abstract

There are two major sources of cholinergic projections in the brain. The nucleus basalis of Meynert provides the principal cholinergic input of the cortical mantle and the pedunculopontine nucleus-laterodorsal tegmental complex (PPN-LDTC; hereafter referred to as PPN) provides the major cholinergic input to the thalamus. Cortical cholinergic denervation has previously been shown to be part of Alzheimer and parkinsonian dementia but there is less information about subcortical thalamic cholinergic denervation. We investigated thalamic cholinergic afferent integrity by measuring PPN-Thalamic (PPN-Thal) acetylcholinesterase (AChE) activity via PET imaging in Alzheimer (AD), Parkinson disease without dementia (PD), Parkinson disease with dementia (PDD) and dementia with Lewy bodies (DLB). AD (n=13; mean age 75.4 ± 5.5), PD (n=11; age 71.4 ± 6.4), PDD (n=6; age 70.8±4.7), DLB (n=6; age 68.0 ± 8.6) and normal controls (NC; n=14; age 69.0 ± 7.5) subjects underwent AChE [¹¹C]-methyl-4-piperidinyl propionate (PMP) PET imaging. PPN-Thal PET data were analyzed using the Nagatsuka method. There were no significant differences in mean age between the groups (F=1.86, p=0.134). Kruskal-Wallis testing demonstrated a significant group effect for PPN-Thal AChE hydrolysis rates (F=9.62, p<0.0001). Compared to NC, reduced thalamic k3 hydrolysis rate was noted in subjects with PDD (-19.8%; AChE k3 hydrolysis rates 0.1072 ± 0.0143 min⁻¹), DLB (-17.4%; 0.1103 ± 0.0112 min⁻¹) and PD (-12.8%; 0.1165 ± 0.0114 min⁻¹). Each of these 3 subgroups was statistically different from AD subjects (-0.7%; 0.1326 ± 0.0095 min⁻¹) who showed relatively spared thalamic k3 hydrolysis rates which were comparable to NC (0.1336 ± 0.0142 min⁻¹). Thalamic cholinergic denervation is present in PD, PDD, and DLB but not in AD. Neurodegenerative involvement of thalamic cholinergic afferent projections may contribute to disease-specific motor and cognitive abnormalities.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22414859      PMCID: PMC3320689          DOI: 10.1016/j.neulet.2012.02.083

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  26 in total

1.  The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's disease.

Authors:  N J Woolf; R W Jacobs; L L Butcher
Journal:  Neurosci Lett       Date:  1989-01-30       Impact factor: 3.046

2.  Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy.

Authors:  J P Brandel; E C Hirsch; S Malessa; C Duyckaerts; P Cervera; Y Agid
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

3.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

4.  Electron microscopy of cholinergic terminals and acetylcholinesterase-containing neurones in the hippocampal formation of the rat.

Authors:  C C Shute; P R Lewis
Journal:  Z Zellforsch Mikrosk Anat       Date:  1966

5.  Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Ronald D Chervin; Kirk A Frey; Nicolaas I Bohnen
Journal:  Ann Neurol       Date:  2012-04       Impact factor: 10.422

6.  Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling.

Authors:  S Nagatsuka Si; K Fukushi; H Shinotoh; H Namba; M Iyo; N Tanaka; A Aotsuka; T Ota; S Tanada; T Irie
Journal:  J Cereb Blood Flow Metab       Date:  2001-11       Impact factor: 6.200

7.  Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons.

Authors:  M M Mesulam; C Geula; M A Bothwell; L B Hersh
Journal:  J Comp Neurol       Date:  1989-05-22       Impact factor: 3.215

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

9.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

Authors:  P J Whitehouse; D L Price; R G Struble; A W Clark; J T Coyle; M R Delon
Journal:  Science       Date:  1982-03-05       Impact factor: 47.728

Review 10.  The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?

Authors:  Marsel Mesulam
Journal:  Learn Mem       Date:  2004 Jan-Feb       Impact factor: 2.460

View more
  26 in total

Review 1.  Sleep-disordered breathing in dementia with Lewy bodies.

Authors:  Raffaele Manni; Michele Terzaghi
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

Review 3.  Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review.

Authors:  Francesco Raudino
Journal:  Neurol Sci       Date:  2013-03-31       Impact factor: 3.307

4.  Parkinson's Disease: What role do pedunculopontine nucleus cholinergic neurons play?

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; William T Dauer; Roger L Albin
Journal:  Future Neurol       Date:  2013-12-16

Review 5.  Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.

Authors:  Paul Noufi; Rita Khoury; Sajeeka Jeyakumar; George T Grossberg
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

6.  Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorder.

Authors:  Shady Rahayel; Malo Gaubert; Ronald B Postuma; Jacques Montplaisir; Julie Carrier; Oury Monchi; David Rémillard-Pelchat; Pierre-Alexandre Bourgouin; Michel Panisset; Sylvain Chouinard; Sven Joubert; Jean-François Gagnon
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

Review 7.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

Review 8.  Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease.

Authors:  Rosie Morris; Douglas N Martini; Tara Madhyastha; Valerie E Kelly; Thomas J Grabowski; John Nutt; Fay Horak
Journal:  Parkinsonism Relat Disord       Date:  2019-02-14       Impact factor: 4.891

9.  Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson's disease patients with defined cholinergic losses.

Authors:  Kamin Kim; Martijn L T M Müller; Nicolaas I Bohnen; Martin Sarter; Cindy Lustig
Journal:  Neuroimage       Date:  2017-02-05       Impact factor: 6.556

Review 10.  Cholinergic dysfunction in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Neurol Neurosci Rep       Date:  2013-09       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.